The Leukemia & Lymphoma Society is Available to Comment on Clinical Trial Results of a Drug Found to Overcome Gleevec Resistance

Posted by rob on November 29, 2004 under Uncategorized | Be the First to Comment

 - Results Will Be Presented Dec. 5 at Annual American Society
                          of Hematology Conference -

    WHITE PLAINS, N.Y., NOV. 29 /PRNewswire/ — Alan Kinniburgh, Senior Vice
President for Research for The Leukemia & Lymphoma Society, is available to
discuss clinical findings showing the overwhelming success of a new drug,
BMS-354825, in overcoming resistance to Gleevec, the frontline therapy for
chronic myelogenous leukemia.
    Dr. Kinniburgh will be available at the American Society of Hematology
conference in San Diego on Sunday, Dec. 5, when the findings of the Phase I
clinical trial will be presented by Charles Sawyers, M.D., the lead
investigator of the team.
    The Leukemia & Lymphoma Society led the way in funding the research that
led up to this clinical trial, with a $7.5 million Specialized Center of
Research (SCOR) grant over a 5-year period.
    To arrange an interview with Dr. Kinniburgh, contact him on his cell phone
at 914-837-6650, or contact Jennifer Corrigan at 732-382-8898 (office), or
732-742-7148 (cell).

 

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/11-29-2004/0002550970&EDATE=